Endothelial Dysfunction Among Woman With Endometriosis

Sponsor
HaEmek Medical Center, Israel (Other)
Overall Status
Recruiting
CT.gov ID
NCT04013126
Collaborator
(none)
100
1
2
40.7
2.5

Study Details

Study Description

Brief Summary

Endometriosis is a chronic disease defined as an ectopic endometrial tissue outside the, and associated with chronic inflammatory state and increased risk of atherosclerosis.

Endothelial dysfunction plays an important and elementary role in the development of atherosclerosis.

There are number of non-invasive tests for evaluating the endothelial function. One of them is FMD - "Flow Mediated Dilatation". Clinical studies proved the efficacy of this method in predicting cardio-vascular events in patients with established heart disease and also as an independent risk factor, better than the traditional ones.

An alternative method, developed in recent years, is evaluation of peripheral blood vessels tone - "Peripheral Arterial Tonometry" - (PAT). It evaluates the pulsatile blood volume of the blood vessels in the fingertips during reactive hyperemia. The obtained value "reactive hyperemic index" (RHI) correlates well with FMD as well with coronary arteries endothelial dysfunction.

it well suited as a clinical tool or as a test for a large-scale clinical study.

Endothelial dysfunction has been demonstrated among woman with endometriosis. After surgical removal of endometrial implants there was a substantial improvement in the endothelial function, by imaging (using FMD) and by inflammatory markers

In this study the investigators will follow the endothelial function among women undergoing endometrial implants surgical removal, before and after the surgery, using PAT technology (ENDOPAT system). Inflammatory markers and quality of life parameters will also be evaluated.

The follow-up will include one meeting 6 weeks after the procedure The investigators expect an improvement in the endothelial function among women who had endometriosis implants removal.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: • Endothelial function using ENDOPAT system
N/A

Detailed Description

Endometriosis is a chronic disease defined as an ectopic endometrial tissue outside the uterus, mostly in the pelvis. It is related to major morbidity and infertility. It is also associated with chronic inflammatory state and increased risk of atherosclerosis.

Endothelial dysfunction plays an important and elementary role in the development of atherosclerosis.

There are number of non-invasive tests for evaluating the endothelial function. One of them is FMD - "Flow Mediated Dilatation". It refers to dilation (widening) of an artery when blood flow increases in that artery after An intentional block of the blood flow. Clinical studies proved the efficacy of this method in predicting cardio-vascular events in patients with established heart disease and also as an independent risk factor, better than the traditional ones.

An alternative method, developed in recent years, is evaluation of peripheral blood vessels tone - "Peripheral Arterial Tonometry" - (PAT). It evaluates the pulsatile blood volume of the blood vessels in the fingertips during reactive hyperemia. The obtained value "reactive hyperemic index" (RHI) correlates well with FMD as well with coronary arteries endothelial dysfunction.

The test is performed by attaching two sensors to the patient's fingertips. Using this method requires short training interval, completely user-independent and the accepted result is a quantitive index. Because it takes only 15 minute to complete the test it well suited as a clinical tool or as a test for a large-scale clinical study.

Endothelial dysfunction has been demonstrated among woman with endometriosis. After surgical removal of endometrial implants there was a substantial improvement in the endothelial function, by imaging (using FMD) and by inflammatory markers, so no difference was shown between them and healthy women, 2 years thereafter.

In a large meta-analysis, evaluating 5,547 patients, every 1% improvement in the FMD scale resulted in a 13% decrease in the rate of cardio-vascular events.

In a meta-analysis evaluating 5,547 patients a 13% reduction in the risk to cardio-vascular events was demonstrated for every 1% improvement in the FMD score.

In this study the investigators will follow the endothelial function among women undergoing endometrial implants surgical removal, before and after the surgery, using PAT technology (ENDOPAT system). Inflammatory markers and quality of life parameters will also be evaluated.

The follow-up will include one meeting 6 weeks after the procedure the investigators expect an improvement in the endothelial function among women who had endometriosis implants removal.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2 groups (treatment, control) each group is evaluated pre and post-surgery2 groups (treatment, control) each group is evaluated pre and post-surgery
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Endothelial Dysfunction Among Woman With Endometriosis After Surgical Treatment
Actual Study Start Date :
Aug 12, 2019
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: endometriosis

Women who undergoing surgery for removal of endometriosis implants

Diagnostic Test: • Endothelial function using ENDOPAT system
All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.

Active Comparator: non-endometriosis

Women who undergoing surgery for removal of benign masses in the pelvis

Diagnostic Test: • Endothelial function using ENDOPAT system
All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline endothelial function at 6 weeks [before and 6 weeks after surgery]

    RHI index - "Reactive Hyperemia Index"

  2. Change from baseline inflammatory markers at 6 weeks [before and 6 weeks after surgery]

    C-reactive protein

Secondary Outcome Measures

  1. Change from baseline pain score at 6 weeks [before and 6 weeks after surgery]

    visual analog scale (VAS)- scale for patient self-reporting of pain. 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, 7-10 represents severe pain). a lower pain level 6 weeks after surgery is a better outcome

  2. Change from baseline quality of life score at 6 weeks [before and 6 weeks after surgery]

    The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. a higher score 6 weeks after surgery is a better outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women who undergoing surgery for removal of endometriosis implants
Exclusion Criteria:
  • Women under 18 or above 60 years of age

  • Women with known vascular disease

  • Women with chronic disease which effect the endothelial function (Diabetes mellitus, Hypertension, Obesity (Defined as BMI≥30), Atherosclerosis, Kidney disease, Collagen disease, Chronic inflammatory disease, and Etc.

  • History of Cardio-vascular event or venous thromboembolism (VTE)

  • Smoking

  • Pregnant women or gave birth in the past 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Haemek Medical Center Afula Israel

Sponsors and Collaborators

  • HaEmek Medical Center, Israel

Investigators

  • Principal Investigator: Eyal Rom, MD, haemek medical center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eyal Rom, MD, Principal Investigator, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT04013126
Other Study ID Numbers:
  • 0100-18-emc
First Posted:
Jul 9, 2019
Last Update Posted:
Jan 25, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 25, 2022